ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, announced that Gencaro atrial fibrillation clinical data from the GENETIC-AF Phase 2B trial have been selected for presentation at the Heart Failure Society of America (HFSA) 2019 Annual Scientific Meeting being held September 13-16 in Philadelphia. William T. Abraham, MD, FACP, FACC, College of Medicine Distinguished Professor, Division of Cardiovascular Medicine at The Ohio State University Wexner Medical Center, will present the data.
“Bucindolol response appears to be greater in heart failure patients with less severe left ventricular dysfunction, a patient population with few therapeutic options for AF prevention or heart failure,” commented Dr. Abraham. “These data provide additional support for pharmacogenetic guided therapy with bucindolol for the prevention of atrial fibrillation in patients with heart failure. We look forward to confirming these important findings in the upcoming Phase 3 PRECISION‑AF trial.”
Abstract Number and Title: 1641, “Pharmacogenetic Guided Beta-blocker Therapy with Bucindolol for the Prevention of Atrial Fibrillation/flutter in Heart Failure: Relationship of Left Ventricular Ejection Fraction to Treatment Effect”
Opening Reception and Poster Reception I: Friday, September 13, 2019; 6:00 – 7:30 p.m. ET
Poster Reception II: Saturday, September 14, 2019; 6:00 – 7:30 p.m. ET
About ARCA biopharma
ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA’s lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the potential treatment of atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted AF prevention treatment. The Gencaro development program has been granted Fast Track designation by FDA. ARCA is also developing AB171, a thiol-substituted isosorbide mononitrate, as a potential genetically-targeted treatment for heart failure and peripheral arterial disease (PAD). For more information, please visit www.arcabio.com.